All In Biotech

Drug Trial Radar · NCT03474965

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis

Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

117

Actual

Start

Oct 1, 2018

Primary completion

Nov 6, 2024

Study completion Nov 6, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 2 to \<18 years with a history of Vaso-Occlusive Crisis (VOC) with or without Hydroxyurea/Hydroxycarbamide (HU/HC), receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was previously demonstrated in adults with sickle cell disease. The approach was to extrapolate from the pharmacokinetics (PK)/pharmacodynamics (PD) already established in the adult population. The study was designed as a Phase II, multicenter, open-label study.

Conditions

  • Sickle Cell Disease (SCD)

Interventions

  • CrizanlizumabDrug

    Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): AUCd15 of Crizanlizumab After First Dose - Part ATime frame: Day 1 to Day 15
  2. Pharmacokinetics (PK) - AUCtau for Serum Crizanlizumab After Multiple Doses - Part A - Steady StateTime frame: Week 15 - Steady state
  3. Pharmacokinetics (PK) - Cmax for Crizanlizumab After First Dose and Multiple Doses - Part A - Steady StateTime frame: Week 1 (after first dose) and Week 15 (steady state)
  4. Pharmacodynamics (PD) - P-selectin Inhibition Parameters for Crizanlizumab After First Dose - Part A - AUCd15Time frame: Day 1 to Day 15
  5. Pharmacodynamics (PD) - P-selectin Inhibition Parameters for Crizanlizumab - Part A - AUCtau After Multiple Dose - Steady StateTime frame: Week 15 - Steady state
  6. Frequency of Any Adverse Events (AEs) as a Measure of Safety and TolerabilityTime frame: Adverse events are reported from the first dose of study treatment until end of study treatment Week 103 plus 105 days post-treatment follow-up, up to a maximum timeframe of approximately 2 years and 3.25 months.

Locations

35 sites in 14 countries. Site status is shown where the registry gives one.

  • University Of Alabama

    Birmingham, Alabama

  • Childrens National Hospital

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • Joe DiMaggio Childrens Hospital

    Hollywood, Florida

  • Childrens Healthcare of Atlanta

    Atlanta, Georgia

  • Childrens Hosp Boston Dept of Hematology

    Boston, Massachusetts

  • Childrens Hospital at Montefiore

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • East Carolina University

    Greenville, North Carolina

  • Childrens Hospital Of Philadelphia

    Philadelphia, Pennsylvania

  • Medical Uni of South Carolina

    Charleston, South Carolina

  • Cook Childrens Medical Center

    Fort Worth, Texas

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Laken, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Montería, Colombia

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Nagpur, Maharashtra, India

  • Novartis Investigative Site

    Padova, PD, Italy

  • Novartis Investigative Site

    Orbassano, TO, Italy

  • Novartis Investigative Site

    Beirut, Lebanon

  • Novartis Investigative Site

    Tripoli, Lebanon

  • Novartis Investigative Site

    Muscat, Oman

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Palma de Mallorca, Balearic Islands, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Adana, Turkey (Türkiye)

  • Novartis Investigative Site

    Mersin, Turkey (Türkiye)

  • Novartis Investigative Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.